Systemically administered alcadein peptide p3-Alcβ neutralizes brain Alzheimer's Aβ oligomers
1Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Psychiatry and Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; James J Peters VA Medical Center, Bronx, NY 10468, USA.
Abstract:
Alcadeins are among the 90 known substrates for γ-secretase, the aspartyl proteinase complex that liberates the amyloid β (Aβ) peptide by intramembranous cleavage of the ß-carboxy terminal fragment of the Alzheimer's amyloid precursor protein (APP). A new study by Hata et al. provides some surprising results regarding a potential role for alcadeins and their fragments in the prevention and/or treatment of the dementia of Alzheimer's disease (AD).
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...


